Jiao Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jiao Shen has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Stephanie K. Dougan
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA
15 shared publications - Abigail E. Witt
Research and Development, Bristol Myers Squibb Company, Cambridge, Massachusetts
13 shared publications - Alba Font-Tello
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts
13 shared publications - Alison Maier
Research and Development, Bristol Myers Squibb Company, Seattle, Washington
13 shared publications - Christopher M. Barbieri
Bristol Myers Squibb, Small Molecule Drug Discovery
13 shared publications - Cloud P. Paweletz
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
13 shared publications
Latest Publications
- Open Access
- 14 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6799) , eadx9954
Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics
Cytokines dimerize two receptor chains to activate Janus kinases and signal transducer and activator of transcription (STAT) transcription factors that regulate immune cells, but they have therapeutic liabilities. We engineered “Trikines” to compel cis formation of three-chain cytokine receptor complexes at the cell surface that induce bespoke STAT transcriptional signaling programs. Trikines coactivated phosphorylation of STAT5 (pSTAT5) and pSTAT3 signatures distinct from natural cytokines by assembling trimeric combinations of interleukin-2 (IL-2), IL-10, and IL-21 receptors. In preclinical models, an IL-2–based Trikine restrained terminal differentiation of T cells, promoted stemness, and enhanced durability of tumor control without observable toxicity. An IL-10–based Trikine induced immune infiltration into poorly immunogenic tumors, showing efficacy in preclinical models of small cell lung cancer and pancreatic cancer. Trikines obviate the need for cell engineering to customize STAT signatures and may hold potential for immunotherapy.
- 14 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6799) , eadx9954
Open AccessRewiring STAT signaling from the cell surface with Trikine immunotherapeutics
Cytokines dimerize two receptor chains to activate Janus kinases and signal transducer and activator of transcription (STAT) transcription factors that regulate immune cells, but they have therapeutic liabilities. We engineered “Trikines” to compel cis formation of three-chain cytokine receptor complexes at the cell surface that induce bespoke STAT transcriptional signaling programs. Trikines coactivated phosphorylation of STAT5 (pSTAT5) and pSTAT3 signatures distinct from natural cytokines by assembling trimeric combinations of interleukin-2 (IL-2), IL-10, and IL-21 receptors. In preclinical models, an IL-2–based Trikine restrained terminal differentiation of T cells, promoted stemness, and enhanced durability of tumor control without observable toxicity. An IL-10–based Trikine induced immune infiltration into poorly immunogenic tumors, showing efficacy in preclinical models of small cell lung cancer and pancreatic cancer. Trikines obviate the need for cell engineering to customize STAT signatures and may hold potential for immunotherapy.
- Open Access
Activation-dependent lentiviruses enable antigen-specific T cell expansion and transduction
Cancer immunotherapies rely on tumor-specific T cells, which arise endogenously in most patients with cancer, but can be low frequency and poorly functional. Methods to specifically identify, expand, and manipulate tumor-specific T cells at the rare frequencies found in peripheral blood would enable new immunotherapeutic strategies. Here, we demonstrate an approach to virally transduce polyclonal tumor-reactive T cells across any MHC haplotype and in the absence of knowing the cognate antigen. By generating lentiviral vectors that selectively transduce cells expressing 4-1BB (CD137), a marker of T cell activation, we can transduce antigen-specific T cells with user-defined genetic cargoes that can selectively expand and track individual clonotypes via single-cell sequencing. Anti-4-1BB lentiviruses (4-1BB LVs) encoding therapeutic cargoes can also enhance antigen-specific T cells to extend survival in a xenograft model of human melanoma and transduce tumor-infiltrating T cells from patients with ovarian cancer. Overall, the 4-1BB LV platform targets antigen-specific T cells in a manner agnostic to both the antigen and presenting MHC, with potential applications in adoptive cell therapy manufacturing and TCR identification. One Sentence Summary: Engineered lentiviral vectors targeting 4-1BB selectively activate, expand, and transduce antigen-specific T cells with immunomodulatory cargo.
Open AccessActivation-dependent lentiviruses enable antigen-specific T cell expansion and transduction
Cancer immunotherapies rely on tumor-specific T cells, which arise endogenously in most patients with cancer, but can be low frequency and poorly functional. Methods to specifically identify, expand, and manipulate tumor-specific T cells at the rare frequencies found in peripheral blood would enable new immunotherapeutic strategies. Here, we demonstrate an approach to virally transduce polyclonal tumor-reactive T cells across any MHC haplotype and in the absence of knowing the cognate antigen. By generating lentiviral vectors that selectively transduce cells expressing 4-1BB (CD137), a marker of T cell activation, we can transduce antigen-specific T cells with user-defined genetic cargoes that can selectively expand and track individual clonotypes via single-cell sequencing. Anti-4-1BB lentiviruses (4-1BB LVs) encoding therapeutic cargoes can also enhance antigen-specific T cells to extend survival in a xenograft model of human melanoma and transduce tumor-infiltrating T cells from patients with ovarian cancer. Overall, the 4-1BB LV platform targets antigen-specific T cells in a manner agnostic to both the antigen and presenting MHC, with potential applications in adoptive cell therapy manufacturing and TCR identification. One Sentence Summary: Engineered lentiviral vectors targeting 4-1BB selectively activate, expand, and transduce antigen-specific T cells with immunomodulatory cargo.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S1. BMS-986408 DGK family selectivity and activity and in T cell functional assays.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S1. BMS-986408 DGK family selectivity and activity and in T cell functional assays.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S2. Additional BMS-986408 mechanism of action data.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S2. Additional BMS-986408 mechanism of action data.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Table S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Table S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S5. Phosphoproteomics analysis of DGKα/ζ dual- and mono- inhibition.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S5. Phosphoproteomics analysis of DGKα/ζ dual- and mono- inhibition.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S7. Additional BMS-986408/CAR-T combination data.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S7. Additional BMS-986408/CAR-T combination data.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Table S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Table S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Table S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Table S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S3. Antigen specific T cell response in the CT26 model.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S3. Antigen specific T cell response in the CT26 model.